Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 0.87 |
| ▸ | BCR | P11274 | 13/20 | 0.87 |
| ▸ | KIT | P10721 | 12/20 | 0.87 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.87 |
| ▸ | ABL2 | P42684 | 3/20 | 0.87 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.87 |
| ▸ | LYN | P07948 | 2/20 | 0.87 |
| ▸ | PLK4 | O00444 | 1/20 | 0.87 |
| ▸ | DDX3X | O00571 | 1/20 | 0.87 |
| ▸ | GAK | O14976 | 1/20 | 0.87 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.87 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.87 |
| ▸ | CA12 | O43570 | 1/20 | 0.87 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.87 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.87 |
| ▸ | EGFR | P00533 | 1/20 | 0.87 |
| ▸ | CA1 | P00915 | 1/20 | 0.87 |
| ▸ | CA2 | P00918 | 1/20 | 0.87 |
| ▸ | LMNA | P02545 | 1/20 | 0.87 |
| ▸ | ALB | P02768 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31553098 | 0.96 | ABL1 (0.94) | ABL1BCRKITPDGFRAABL2 | |
| SCHEMBL12127861 | 0.94 | ABL1 (0.90) | ABL1BCRKITPDGFRAABL2 | |
| Imatinib SCHEMBL29355523 | 0.93 | ABL1 (1.00) | ABL1BCRKITPDGFRAABL2 | |
| Imatinib SCHEMBL3827 | 0.93 | ABL1 (1.00) | ABL1BCRKITPDGFRAABL2 | |
| SCHEMBL10074443 | 0.93 | ABL1 (0.88) | ABL1BCRKITPDGFRAABL2 | |
| Imatinib SCHEMBL29351601 | 0.93 | ABL1 (1.00) | ABL1BCRKITPDGFRAABL2 | |
| SCHEMBL4394235 | 0.93 | ABL1 (0.88) | ABL1BCRKITPDGFRAABL2 | |
| Imatinib SCHEMBL2236091 | 0.93 | ABL1 (1.00) | ABL1BCRKITPDGFRAABL2 | |
| SCHEMBL4394539 | 0.93 | ABL1 (0.88) | ABL1BCRKITPDGFRAABL2 | |
| SCHEMBL12288611 | 0.93 | ABL1 (1.00) | ABL1BCRKITPDGFRAABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2471529-A2 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | Emory University (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2364702-A2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | Emory University (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2008079460-A2 | TYROSINE KINASE INHIBITORS FOR PREVENTION OR TREATMENT OF INFECTION | EMORY UNIVERSITY (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | MAP3K1, MAP3K2, MAP3K6 | ABL1 21/4885BCR 1003/4885KIT 1765/4885 |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | MAP3K1, MAP3K2, MAP3K6 | ABL1 21/4885BCR 1003/4885KIT 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.